Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc

Bullboard Posts

Comment by Stocktreeon Oct 03, 2016 11:00pm

150 Views

Post# 25305270

RE:A little "intra-abdominal focus" at the end of the trial?

Hi there SWYG, I am starting to understand this post, which is one of your best for me. You say "101 into the last 180". It will not matter much, but shouldn't it be 101 into the last 176, hence the "Recruiting the Last 75 Patients"?

Bullboard Posts

NervGen Pharma: Proof that NVG-291 works?